Mirna Therapeutics Lands $41,800,000 Series D Financing Round

  • Feed Type
  • Date
    4/30/2015
  • Company Name
    Mirna Therapeutics
  • Mailing Address
    2150 Woodward St. Austin, TX 78744 USA
  • Company Description
    Mirna Therapeutics, Inc., traces its lineage back to Ambion, Inc., a privately held company that offered research reagents for RNA analysis. It was at Ambion where Mirna’s miRNA therapeutic research and development program began in 2002 when the first molecular biology tools were developed for studying miRNAs.
  • Website
    http://www.mirnatherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $41,800,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    The funding will enable Mirna to advance its lead microRNA (miRNA) therapeutic product candidate, MRX34, into Phase 1b and Phase 2 trials in 2016. Indications for further development will be selected at the completion of Mirna’s ongoing Phase 1 trial in patients with hepatocellular carcinoma, other solid tumors and hematological malignancies. The Company also plans to advance a second miRNA therapeutic candidate into clinical trials with the proceeds of this financing, as well as embark on a combination therapy development program.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy